welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

key information

study id #: NCT02329769

condition: Duchenne Muscular Dystrophy

status: terminated


The purpose of this study is to see whether PRO044 is safe and effective to use as medication for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 44 in the DNA for the dystrophin protein.

intervention: PRO044 SC 6 mg/kg, PRO044 IV 6 mg/kg, PRO044 IV 9 mg/kg

mechanism of action: Exon-skipping to promote dystrophin production

results: https://clinicaltrials.gov/ct2/show/results/NCT02329769

last updated: November 22, 2018